Altimmune, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ALT | GYRE | GNFT.PA | IVA | 24H.F | AGMB | |
|---|---|---|---|---|---|---|
| Market cap | 412.38M | 470.79M | 574.36M | 914.17M | 352.86M | 337.35M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -3.2 | 74.0 | 63.8 | -5.2 | — | -3.4 |
| Price/book | 0.9 | 4.4 | -11.8 | 13.8 | -0.5 | 2.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −46.19% | −39.92% | +218.29% | −7.42% | +37.87% | −53.24% |
| Today | +3.92% | 0.00% | +3.04% | −3.97% | −0.23% | 0.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ALT news ›Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
As part of this transition, John M. Gill, Mitchel Sayare, Ph.D., and Klaus O. Schafer, M.D., MPH, will retire from the Board at the Company’s 2027 Annual Meeting MORRISTOWN, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:…
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing ... Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference GAITHERSBURG,…
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026
Clinical highlights from the IMPACT Phase 2b study of pemvidutide in MASH demonstrated improvements in liver fibrosis and inflammation with generally favorable gastrointestinal tolerability Oral presentation to feature new pre-clinical…
Grifols (NASDAQ:GRFS) versus Altimmune (NASDAQ:ALT) Head-To-Head Contrast
Posted by Sarita Garza on Oct 25th, 2026 Grifols (NASDAQ:GRFS – Get Free Report) and Altimmune (NASDAQ:ALT – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on…
More from 1 other outlet
Critical Contrast: GeoVax Labs (NASDAQ:GOVX) & Altimmune (NASDAQ:ALT)
Posted by Kim Johansen on Oct 24th, 2026 GeoVax Labs (NASDAQ:GOVX – Get Free Report) and Altimmune (NASDAQ:ALT – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses…
Analysts Are Bullish on These Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Altimmune (ALT)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Madrigal Pharmaceuticals (MDGL) and Altimmune (ALT) with bullish sentiments. In a report released yesterday, Andrew Fein from H.C. Wainwright…
Altimmune price target lowered to $17 from $18 at Evercore ISI
Evercore ISI analyst Michael DiFiore lowered the firm’s price target on Altimmune (ALT) to $17 from $18 and keeps an Outperform rating on the sh... Altimmune price target lowered to $17 from $18 at Evercore ISI Evercore ISI analyst Michael…
Altimmune management to meet with Truist
Analyst Devarakonda holds a meeting with management. in Boston on October 8 hosted by Truist. Published first on TheFly – the ultimate source f... Altimmune management to meet with Truist Analyst Devarakonda holds a meeting with…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com6
- themarketsdaily.com2
- defenseworld.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.